NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Caribou Biosciences, Inc. (CRBU) Stock Analysis

Caribou Biosciences, Inc. (CRBU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CRBU

$0.54

+$0.03 (+4.89%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRBU with… →

CRBU Key Statistics

As of Oct 21, 2026
Trading
Open
$0.52
Previous Close
$0.52
Day's Range
0.51–0.55
52-Week Range
0.44–3.54
Volume
2.26M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.31
Valuation
Market Cap
$58.36M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.82
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.08
Financials (FY)
Revenue (FY)
$11.16M+11.66%
Net Income (FY)
−$148.13M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
107.21M
1-Year Return
−80.83%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
2.45M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CRBU closed at $0.54, −80.83% over 1 year.

Caribou Biosciences, Inc. (CRBU) has a market capitalization of $58.36M.

In fiscal 2025, CRBU reported revenue of $11.16M.

CRBU Stock Return by Calendar Year

Caribou Biosciences, Inc. (CRBU) return since Jul 2021: what $10,000 became

1 year
$10,000 $1,917
−80.83%
5 years
$10,000 $270
−97.30%
Since Jul 2021
$10,000 $334
−96.66%

If you had invested $10,000 in Caribou Biosciences, Inc. (CRBU) at the close on July 23, 2021, the earliest close on record here, it would have been worth $334 at the close on October 21, 2026: −96.66% in total, −47.70% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−65.76%
2025+0.00%
2024−72.25%
2023−8.76%
2022−58.38%
2021 (partial year)−7.54%

As of October 21, 2026.

CRBU Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$11.16M−$148.13M−1,327.4%
2024$9.99M−$149.11M−1,491.9%
2023$34.48M−$102.07M−296.1%
2022$13.85M−$99.42M−717.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$11.16M—−$136.19M−$148.13M−1,327.4%
2024$9.99M—−$166.62M−$149.11M−1,491.9%
2023$34.48M—−$116.06M−$102.07M−296.1%
2022$13.85M—−$106.40M−$99.42M−717.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRBU Valuation vs Biotechnology Median

Median of 608 stocks
MetricCRBUBiotechnology medianvs median
P/S ratio5.8213.3056% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Caribou Biosciences, Inc. (CRBU) at $58.36M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 97.

The 52-week range on file runs from $0.44 to $3.54. The most recent close on file for CRBU is $0.54, dated October 21, 2026. That is +$0.03 (+4.89%) against the previous close. The latest close sits 22.89% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $11.16M. That is +11.66% against the prior fiscal year, when revenue was $9.99M. The same year closed with a net loss of $148.13M. Trailing earnings per share are −1.08.

Across the 4 fiscal years on file, revenue moves from $13.85M in 2022 to $11.16M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 5.82 times revenue. On price-to-sales that is 56.27% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 2.31. Daily returns over the trailing 5 years annualize to a volatility of 86.93%. Over the trailing twelve months the total return is −80.83%. Measured over 5 years, that is −51.45% a year compounded.

Growth & Income

No dividend is on file for CRBU.

2026 is still running; the total return is −65.76% year to date. Across the complete calendar years on file, 2025 returned 0.00% and 2024 returned −72.25%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Caribou Biosciences, Inc. (CRBU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Caribou Biosciences, Inc. CRBU $58.36M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Caribou Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Visit website →